Neurocrine Biosciences (NASDAQ:NBIX)
has a lot on the line in 2015, as the company will see pivotal data on
its two late-stage clinical compounds (Elagolix and NBI-98854, or '854)
and these reports will have significant impacts on the value of the
shares.
So far, so good. Neurocrine's partner AbbVie (NYSE:ABBV)
announced positive top-line data from the VIOLET PETAL Phase III study
of Elagolix in endometriosis on Thursday morning. While the release was
spartan and investors will have to wait until later in the year for more
details, the positive efficacy and consistent safety data nevertheless
do help de-risk the program for Neurocrine shareholders.
Although
Neurocrine shares don't look exceptionally cheap in the immediate
aftermath of this data release, the potential of further positive
releases can't be ignored. Should the pivotal study of '854 in tardive
dyskinesia succeed, another $5/share or more in value could be unlocked,
not to mention the potential value of clinical updates on Elagolix in
uterine fibroids, '854 in Tourette's, and NBI-77860 ('860) in congential
adrenal hyperplasia.
Continue here:
Neurocrine Biosciences Starts A Data-Rich Year On The Right Foot
No comments:
Post a Comment